AF and diabetes: DOAC better than warfarin for cardiac and limb events

Rivaroxaban is associated with fewer major adverse cardiac events (MACE) and major adverse limb events (MALE) than warfarin in patients with non-valvular atrial fibrillation and comorbid type 2 diabetes, a study shows. A retrospective claims analysis in the US of more than 10,000 patients on rivaroxaban and almost 14,000 warfarin users found rivaroxaban was associated ...

Already a member?

Login to keep reading.

© 2021 the limbic